A randomized double-blind placebo-controlled study of ALPN-101 in systemic lupus erythematosus.
Brief description of study
Subjects will be evaluated during a screening period of 42 days. Screening laboratory evaluations and disease activity assessments will be performed by the Investigator and reviewed by the sponsor to determine eligibility. Subjects will return for the Baseline visit to undergo assessment and confirmation of disease activity by the Investigator. Subjects who are eligible will be randomized to receive blinded study drug every 2 weeks for a total of 12 doses of 3mg/kg ALPN-101 or placebo.
Clinical Study Identifier: s20-01776
ClinicalTrials.gov Identifier: NCT04835441
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
